tiprankstipranks
Adma Biologics sees FY26 revenue $600M
The Fly

Adma Biologics sees FY26 revenue $600M

Sees FY26 net income expected to exceed $230M; FY26 adjusted EBITDA expected to exceed $300M

Stay Ahead of the Market:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App

Latest News Feed

More Articles